Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)

Conditions

• Pulmonary Disease, Chronic Obstructive

Eligibility Criteria

Sex

ALL

Age

40 Years - 80 Years

Healthy Volunteers

Not accepted

Interventions

• Depemokimab — DRUG
  Depemokimab as a sterile liquid formulation will be administered.
• Placebo — DRUG
  Placebo as a sterile 0.9 percent (%) sodium chloride solution will be administered

Study Details

Depemokimab is being developed as a treatment for individuals with moderate to severe COPD. The aim of this study is to assess the efficacy and safety of depemokimab compared as an add-on medicine in participants with uncontrolled moderate to severe COPD with type 2 inflammation.

Key Dates

Start date

Jun 23, 2025

Status verified

Apr 2026

Primary completion

Aug 21, 2029

Completion

Aug 21, 2029

Study Design

Enrollment

960 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: Depemokimab
  Participants will be administered subcutaneous (SC) injection of Depemokimab along with standard of care (SoC).
• Placebo Comparator: Placebo
  Participants will be administered placebo along with SoC.

Primary Outcome Measure

Annualized Rate of Moderate/Severe Exacerbations [ Time Frame: From Baseline up to Week 104 ]

Central Contacts

• US GSK Clinical Trials Call Center
  877-379-3718
  [email protected]
• EU GSK Clinical Trials Call Center
  +44 (0) 20 89904466
  [email protected]

Locations (55)

Find similar trials in Sheffield, AL

Related Studies

• Trial to Determine Effective Aspirin Dose in COPD
  PHASE3 · Recruiting · Johns Hopkins University · Baltimore, Maryland
• A Study of the Effect of a Nurse Navigator Program on High Risk Patients
  Not Yet Recruiting · Mayo Clinic · Jacksonville, Florida
• Hypoxia and Heart Rate Variability
  Not Yet Recruiting · University of Miami · Miami, Florida
• Pragmatic Trial to Enhance Quality Safety, and Patient Experience in COPD
  Recruiting · Seattle Institute for Biomedical and Clinical Research · Minneapolis, Minnesota